Beta Blockers can Mask not only Hypoglycemia but also Hypotension

Goran      Koracevic; Sladjana      Micic; Milovan      Stojanovic; Radmila   Velickovic   Radovanovic; Milan      Pavlovic; Tomislav      Kostic; Dragan      Djordjevic; Nebojsa      Antonijevic; Maja      Koracevic; Vesna      Atanaskovic; Sonja      Dakic
doi:10.2174/1381612828666220421135523
Abstract

Background: Beta-adrenergic (β-AR) receptor blockers (BBs) are an essential class of drugs as they have numerous indications. On the other hand, they have numerous unwanted effects that decrease the compliance, adherence, and persistence of this very useful group of drugs.
Objective: The paper aims to analyze the possibility that an unnoticed side effect may contribute to a less favorable pharmacologic profile of BBs, e.g., a diminished reaction to a sudden fall in BP.
Methods: We searched two medical databases for abstracts and citations (Medline and SCOPUS). Moreover, we searched the internet for drug prescription leaflets (of the individual BBs).
Results: Whichever cause of stress is considered, the somatic manifestations of stress will be (partially) masked if a patient takes BB. Stress-induced hypercatecholaminemia acts on β-AR of cardiomyocytes; it increases heart rate and contractility, effects suppressed by BBs. The answers of the organism to hypoglycemia and hypotension share the main mechanisms such as sympathetic nervous system activation and hypercatecholaminemia. Thus, there is a striking analogy: BBs can cover up symptoms of both hypoglycemia (which is widely known) and of hypotension (which is not recognized). It is widely known that BBs can cause hypotension. However, they can also complicate recovery by spoiling the defense mechanisms in hypotension as they interfere with the crucial compensatory reflex to increase blood pressure in hypotension.
Conclusion: Beta blockers can cause hypotension, mask it, and make recovery more difficult. This is clinically important and deserves to be more investigated and probably to be stated as a warning.
Keywords: Beta blockers, arterial hypotension, hypoglycemia, side effects, adherence, heart failure.
« Previous Next »
[1] 
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J  2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID:  30165516] 
[2] 
Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res  2019; 42(9): 1235-481.
[http://dx.doi.org/10.1038/s41440-019-0284-9] [PMID:  31375757] 
[3] 
Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension  2020; 75(6): 1334-57.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15026] [PMID:  32370572] 
[4] 
Koracevic G, Micic S, Stojanovic M, et al. Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class. Curr Vasc Pharmacol  2021; 19(4): 343-6.
[http://dx.doi.org/10.2174/1570161118666200518113833] [PMID:  32418526] 
[5] 
Diaconu CC, Marcu DR, Bratu OG, et al. Beta-blockers in cardiovascular therapy: A Review. J Mind Med Sci  2019; 6(2): 216-23.
[http://dx.doi.org/10.22543/7674.62.P216223] 
[6] 
Koracevic G, Micic S, Stojanovic M, et al. Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies. Hypertens Res  2020; 43(7): 591-6.
[http://dx.doi.org/10.1038/s41440-020-0449-6] [PMID:  32382156] 
[7] 
Patel PH, Nguyen M, Rodriguez R, Surani S, Udeani G. Omecamtiv mecarbil: A novel mechanistic and therapeutic approach to chronic heart failure management. Cureus  2021; 13(1): e12419.
[http://dx.doi.org/10.7759/cureus.12419] [PMID:  33542867] 
[8] 
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J  2020; 41(3): 407-77.
[http://dx.doi.org/10.1093/eurheartj/ehz425] [PMID:  31504439] 
[9] 
van Diepen S, Armstrong PW. Learning whether to subtract beta-blockers: It’s about time. Eur Heart J  2021; 42(9): 915-8.
[http://dx.doi.org/10.1093/eurheartj/ehaa1033] [PMID:  33428708] 
[10] 
Shitara J, Naito R, Kasai T, et al. Differing effects of beta-blockers on long-term clinical outcomes following percutaneous coronary intervention between patients with mid-range and reduced left ventricular ejection fraction. BMC Cardiovasc Disord  2021; 21(1): 36.
[http://dx.doi.org/10.1186/s12872-021-01850-9] [PMID:  33446110] 
[11] 
Volpe M, Mastromarino V, Santolamazza C. Historical overview: Beta-Blockers in hypertension and cardiovascular disease. Springer Healthcare Italia 2019.
[12] 
Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: The future of treatment. Eur J Heart Fail  2020; 22(2): 228-40.
[http://dx.doi.org/10.1002/ejhf.1715] [PMID:  31919938] 
[13] 
Antunes MO, Scudeler TL. Hypertrophic cardiomyopathy. Int J Cardiol Heart Vasc  2020; 27: 100503.
[http://dx.doi.org/10.1016/j.ijcha.2020.100503] [PMID:  32309534] 
[14] 
Farzam K, Jan A. Beta Blockers. Treasure Island, FL: StatPearls Publishing 2020.
[15] 
 Scottish Intercollegiate Guidelines Network (SIGN). Management of stable angina. Edinburgh: SIGN; 2018. (SIGN publication no. 151). 2018. Available from: http://www.sign.ac.uk
[16] 
Tucker WD, Sankar P, Kariyanna T. Selective Beta-1-Blockers. Treasure Island, FL: StatPearls Publishing 2021.
[17] 
Garcia-Tsao G. The use of nonselective beta blockers for treatment of portal hypertension. Gastroenterol Hepatol (N Y)  2017; 13(10): 617-9.
[PMID:  29230139] 
[18] 
Lim KP, Loughrey S, Musk M, Lavender M, Wrobel JP. Beta-blocker under-use in COPD patients. Int J Chron Obstruct Pulmon Dis  2017; 12: 3041-6.
[http://dx.doi.org/10.2147/COPD.S144333] [PMID:  29089752] 
[19] 
Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: The good, the bad and the ugly. Curr Opin Pulm Med  2021; 27(2): 125-31.
[http://dx.doi.org/10.1097/MCP.0000000000000748] [PMID:  33332878] 
[20] 
Bakris G, Ali W, Parati G. ACC/AHA versus ESC/ESH on hypertension guidelines: Jacc guideline comparison. J Am Coll Cardiol  2019; 73(23): 3018-26.
[http://dx.doi.org/10.1016/j.jacc.2019.03.507] [PMID:  31196460] 
[21] 
Mancia G. β-Blockers and Guidelines Beta-blockers in hypertension and cardiovascular disease. Springer Healthcare Italia 2019.
[22] 
Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. The safety of cardioselective β1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports. ERJ Open Res  2021; 7(1): 00801-2020.
[http://dx.doi.org/10.1183/23120541.00801-2020] [PMID:  33681344] 
[23] 
Huang KY, Tseng PT, Wu YC, et al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of ran-domized controlled trials. Sci Rep  2021; 11(1): 452.
[http://dx.doi.org/10.1038/s41598-020-79837-3] [PMID:  33432057] 
[24] 
Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarc-tion without reduced ejection fraction: Study protocol for a randomized controlled trial. Trials  2020; 21(1): 415.
[http://dx.doi.org/10.1186/s13063-020-4214-6] [PMID:  32446298] 
[25] 
Rhee MY, Kim CH, Ahn Y, et al. Efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with concomitant hypertension and hyperlipidemia. Drug Des Devel Ther  2020; 14: 5005-17.
[http://dx.doi.org/10.2147/DDDT.S280055] [PMID:  33235439] 
[26] 
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J  2016; 37(29): 2315-81.
[http://dx.doi.org/10.1093/eurheartj/ehw106] [PMID:  27222591] 
[27] 
Koracevic G, Micic S, Stojanovic M. By discontinuing beta-blockers before an exercise test we may precipitate a rebound phenomenon. Curr Vasc Pharmacol  2021; 19(6): 624-33. [e-pub ahead of print]
[http://dx.doi.org/10.2174/1570161119666210302152322] [PMID:  33653252] 
[28] 
Singh S, Ricardo-Silgado ML, Bielinski SJ, Acosta A. Pharmacogenomics of medication-induced weight gain and antiobesity medications. Obesity (Silver Spring)  2021; 29(2): 265-73.
[http://dx.doi.org/10.1002/oby.23068] [PMID:  33491309] 
[29] 
Desta L, Khedri M, Jernberg T, et al. Adherence to beta-blockers and long-term risk of heart failure and mortality after a myocardial infarction. ESC Heart Fail  2021; 8(1): 344-55.
[http://dx.doi.org/10.1002/ehf2.13079] [PMID:  33259148] 
[30] 
Andersson C, Shilane D, Go AS, et al. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol  2014; 64(3): 247-52.
[http://dx.doi.org/10.1016/j.jacc.2014.04.042] [PMID:  25034059] 
[31] 
Thome J, David Byon D. Addressing hypoglycemic emergencies. US Pharm  2018; 43(10): HS2-6.
[32] 
Beattie WS, Hare GM. Beta-blockers are the old BLACK. Can J Anesth/J can d'anesth  2014; 61(9): 787-93.
[http://dx.doi.org/10.1007/s12630-014-0199-5] 
[33] 
Noyes R Jr. Beta-adrenergic blocking drugs in anxiety and stress. Psychiatr Clin North Am  1985; 8(1): 119-32.
[http://dx.doi.org/10.1016/S0193-953X(18)30713-5] [PMID:  2859576] 
[34] 
Blessberger H, Kammler J, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev  2014; (9): CD004476.
[http://dx.doi.org/10.1002/14651858.CD004476.pub2] 
[35] 
Fragata J. Beta-blockers: Protective against perioperative stress, but not for all - as the evidence shows. Rev Port Cardiol  2019; 38(10): 695-6.
[http://dx.doi.org/10.1016/j.repce.2020.01.003] [PMID:  31964556] 
[36] 
Bellis A, Mauro C, Barbato E, Ceriello A, Cittadini A, Morisco C. Stress-induced hyperglycaemia in non-diabetic patients with acute coronary syndrome: From molecular mechanisms to new therapeutic perspectives. Int J Mol Sci  2021; 22(2): 775.
[http://dx.doi.org/10.3390/ijms22020775] [PMID:  33466656] 
[37] 
Prasad Hrishi A, Ruby Lionel K, Prathapadas U. Head rules over the heart: Cardiac manifestations of cerebral disorders. Indian J Crit Care Med  2019; 23(7): 329-35.
[http://dx.doi.org/10.5005/jp-journals-10071-23208] [PMID:  31406441] 
[38] 
Jørgensen ME, Andersson C, Venkatesan S, Sanders RD. Beta-blockers in noncardiac surgery: Did observational studies put us back on safe ground? Br J Anaesth  2018; 121(1): 16-25.
[http://dx.doi.org/10.1016/j.bja.2018.02.004] [PMID:  29935568] 
[39] 
Pham D, Ward H, Yong B, et al. Is lactate lower in septic patients who are prescribed beta blockers? Retrospective cohort study of an intensive care population. Emerg Med Australas  2021; 33(1): 82-7.
[http://dx.doi.org/10.1111/1742-6723.13584] [PMID:  32808473] 
[40] 
Guz D, Buchritz S, Guz A, et al. Beta-Blockers, tachycardia and survival following sepsis-an observational cohort study. Clin Infect Dis  2021; ciab034.
[http://dx.doi.org/10.1093/cid/ciab034] 
[41] 
Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: A systematic review. Br J Anaesth  2018; 121(4): 706-21.
[http://dx.doi.org/10.1016/j.bja.2018.04.036] [PMID:  30236233] 
[42] 
Donaldson J, Haddad B, Khan WS. The pathophysiology, diagnosis and current management of acute compartment syndrome. Open Orthop J  2014; 8(1): 185-93.
[http://dx.doi.org/10.2174/1874325001408010185] [PMID:  25067973] 
[43] 
Salmasi V, Maheshwari K, Yang D, et al. Relationship between intraoperative hypotension, defined by either reduction from baseline or absolute thresholds, and acute kidney and myocardial injury after noncardiac surgery: A retrospective cohort analysis. Anesthesiology  2017; 126(1): 47-65.
[http://dx.doi.org/10.1097/ALN.0000000000001432] [PMID:  27792044] 
[44] 
Brady KM, Hudson A, Hood R, DeCaria B, Lewis C, Hogue CW. Personalizing the definition of hypotension to protect the brain. Anesthesiology  2020; 132(1): 170-9.
[http://dx.doi.org/10.1097/ALN.0000000000003005] [PMID:  31644437] 
[45] 
Ziegler MG. Atherosclerosis and blood pressure variability. Hypertension  2018; 71(3): 403-5.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.117.10481] [PMID:  29295854] 
[46] 
Kong Q, Ma X, Wang C, Du X, Ren Y, Wan Y. Total atherosclerosis burden of baroreceptor-resident arteries independently predicts blood pressure dipping in patients with ischemic stroke. Hypertension  2020; 75(6): 1505-12.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15036] [PMID:  32336234] 
[47] 
Bhalke RD, Giri MA, Anil RY, Balasaheb NM, Nanasaheb PA, Pande VV. Hypotension: A comprehensive review. J Pharmacogn Phytochem  2021; 10(1): 1945-7.
[48] 
Lundqvist MH, Almby K, Wiklund U, et al. Altered hormonal and autonomic nerve responses to hypo- and hyperglycaemia are found in overweight and insulin-resistant individuals and may contribute to the development of type 2 diabetes. Diabetologia  2021; 64(3): 641-55.
[http://dx.doi.org/10.1007/s00125-020-05332-z] [PMID:  33241460] 
[49] 
Sejling AS, Wang P, Zhu W, et al. Repeated activation of noradrenergic receptors in the ventromedial hypothalamus suppresses the re-sponse to hypoglycemia. Endocrinology  2021; 162(3): bqaa241.
[http://dx.doi.org/10.1210/endocr/bqaa241] 
[50] 
Sheehan A, Patti ME. Hypoglycemia after upper gastrointestinal surgery: Clinical approach to assessment, diagnosis, and treatment. Diabetes Metab Syndr Obes  2020; 13: 4469-82.
[http://dx.doi.org/10.2147/DMSO.S233078] [PMID:  33239898] 
[51] 
Koraćević G, Mićić S, Stojanović M, et al. Single prognostic cutoff
value for admission glycemia in acute myocardial infarction
has been used although high-risk stems from hyperglycemia as
well as from hypoglycemia (a narrative review). Prim Care Diabetes  2020; 14(6): 594-604.
[http://dx.doi.org/10.1016/j.pcd.2020.09.004] [PMID: 32988774] 
[52] 
Simsek Y, Karaca Z, Diri H, Tanriverdi F, Unluhizarci K, Kelestemur F. Is biochemical hypoglycemia necessary during an insulin toler-ance test? Arch Endocrinol Metab  2020; 64(1): 82-8.
[http://dx.doi.org/10.20945/2359-3997000000200] [PMID:  32187262] 
[53] 
Sharma S, Hashmi MF, Bhattacharya PT. Hypotension. Treasure Island, FL: StatPearls Publishing 2021.
[54] 
Chen Z, Shao DH, Ma XD, Mao ZM. Dexmedetomidine aggravates hypotension following mesenteric traction during total gastrectomy: A randomized controlled trial. Ann Saudi Med  2020; 40(3): 183-90.
[http://dx.doi.org/10.5144/0256-4947.2020.183] [PMID:  32493029] 
[55] 
Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol  2018; 72(11): 1294-309.
[http://dx.doi.org/10.1016/j.jacc.2018.05.079] [PMID:  30190008] 
[56] 
Goldstein DS. Catecholamines and stress. Endocr Regul  2003; 37(2): 69-80.
[PMID:  12932192] 
[57] 
Thau L, Gandhi J, Sharma S. Physiology, Cortisol. Treasure Island, FL: StatPearls Publishing 2021.
[58] 
Mokrousov IS, Perfilova VN, Prokofiev II, et al. Effect of a new cyclic derivative of GABA, RGPU-207, on the functions of cardiac and cerebral mitochondria of stressed animals. J Pharm Pharmacol  2019; 71(7): 1055-64.
[http://dx.doi.org/10.1111/jphp.13086] [PMID:  30864160] 
[59] 
Long C, Dungan K. Hypoglycemia awareness and burden among hospitalized patients at high risk for hypoglycemia. J Diabetes Complications  2020; 34(4): 107521.
[http://dx.doi.org/10.1016/j.jdiacomp.2019.107521] [PMID:  31937469] 
[60] 
Laurent S. Antihypertensive drugs. Pharmacol Res  2017; 124: 116-25.
[http://dx.doi.org/10.1016/j.phrs.2017.07.026] [PMID:  28780421] 
[61] 
Ecks S. Depression, deprivation, and dysbiosis: Polyiatrogenesis in multiple chronic illnesses. Cult Med Psychiatry  2021; 45(4): 507-24. [e-pub ahead of print]
[http://dx.doi.org/10.1007/s11013-020-09699-x] [PMID:  33547618] 
[62] 
Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. Cardiovasc Diabetol  2019; 18(1): 163.
[http://dx.doi.org/10.1186/s12933-019-0967-1] [PMID:  31775749] 
[63] 
Makin S, Stott DJ. Managing blood pressure in older adults. BMJ  2018; 362: k2912.
[http://dx.doi.org/10.1136/bmj.k2912] [PMID:  29980562] 
[64] 
Rhyu YA, Jang JY, Park S, et al. Impaired cortisol and growth hormone counterregulatory responses among severe hypoglycemic pa-tients with type 2 diabetes mellitus. Endocrinol Metab (Seoul)  2019; 34(2): 187-94.
[http://dx.doi.org/10.3803/EnM.2019.34.2.187] [PMID:  31257746] 
[65] 
Lager I, Jagenburg R, von Schenck H, Smith U. Effect of beta-blockade on hormone release during hypoglycaemia in insulin-dependent diabetics. Acta Endocrinol (Copenh)  1980; 95(3): 364-71.
[http://dx.doi.org/10.1530/acta.0.0950364] [PMID:  6108035] 
[66] 
Bokhari S, Plummer E, Emmerson P, Gupta A, Meyer C. Glucose counterregulation in advanced type 2 diabetes: Effect of β-adrenergic blockade. Diabetes Care  2014; 37(11): 3040-6.
[http://dx.doi.org/10.2337/dc14-0782] [PMID:  25092686] 
[67] 
Kerr D, MacDonald IA, Heller SR, Tattersall RB. Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol  1990; 29(6): 685-93.
[http://dx.doi.org/10.1111/j.1365-2125.1990.tb03689.x] [PMID:  1974143] 
[68] 
Clausen-Sjöbom N, Lins PE, Adamson U, Curstedt T, Hamberger B. Effects of metoprolol on the counter-regulation and recognition of prolonged hypoglycemia in insulin-dependent diabetics. Acta Med Scand  1987; 222(1): 57-63.
[http://dx.doi.org/10.1111/j.0954-6820.1987.tb09929.x] [PMID:  3307308] 
[69] 
Coop CA, Schapira RS, Freeman TM, Are ACE. Inhibitors and beta-blockers dangerous in patients at risk for anaphylaxis? J Allergy Clin Immunol Pract  2017; 5(5): 1207-11.
[http://dx.doi.org/10.1016/j.jaip.2017.04.033] [PMID:  28552379] 
[70] 
Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: Epidemiology, prognosis, and treatment. J Am Coll Cardiol  2015; 66(7): 848-60.
[http://dx.doi.org/10.1016/j.jacc.2015.06.1084] [PMID:  26271068] 
[71] 
Perez CM, Hazari MS, Farraj AK. Role of autonomic reflex arcs in cardiovascular responses to air pollution exposure. Cardiovasc Toxicol  2015; 15(1): 69-78.
[http://dx.doi.org/10.1007/s12012-014-9272-0] [PMID:  25123706] 
[72] 
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM. Cochrane corner: Beta-blockers for hypertension. Heart  2018; 104(4): 282-3.
[http://dx.doi.org/10.1136/heartjnl-2017-311585] [PMID:  28756403] 
[73] 
Holm H, Ricci F, Di Martino G, et al. Beta-blocker therapy and risk of vascular dementia: A population-based prospective study. Vascul Pharmacol  2020; 125-126: 106649.
[http://dx.doi.org/10.1016/j.vph.2020.106649] [PMID:  31958512] 
[74] 
Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The association between orthostatic hypotension and medication use in the British Women’s Heart and Health Study. Age Ageing  2010; 39(1): 51-6.
[http://dx.doi.org/10.1093/ageing/afp192] [PMID:  19897539] 
[75] 
 BISOPROLOL SANDOZ® (bisoprolol fumarate) Consumer Medicine
Information (leaflet revised in March 2021). Sandoz Pty Ltd.
Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-CMI-01404-3&d=202103311016933
[76] 
 APO-Bisoprolol (Bisoprolol fumarate) Consumer Medicine Information
(Leaflet updated in 2020). Apotex Inc. Available from: https://media.healthdirect.org.au/medicines/GuildLink_Information/182114/CMI/txcbisop10720.pdf
[77] 
 Bisoprolol HCT STADA (Bisoprolol/ Hydrochlorothiazide) Package
leaflet: Information for the user (2020). STADA Arzneimittel
AG. Available from: https://file.wuxuwang.com/hma/BE_H_0126_001_FinalPL.pdf
[78] 
 Bisoprolol Mylan (bisoprolol fumarate) Package leaflet: Information
for the patient. Mylan 2019. Available from: https://www.hpra.ie/img/uploaded/swedocuments/064e8a00-7872-48a0-b0e7-88d2698293cc.pdf
[79] 
 Bisoprolol generichealth (bisoprolol fumarate) Consumer medicine
information. Generic Health 2020. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-CMI-02590-1&d=202103301016933
[80] 
 BISOPROLOL SANDOZ® (bisoprolol fumarate) Consumer Medicine
Information (Leaflet revised in2011). Sandoz Pty Ltd. Available
from: https://gp2u.com.au/static/pdf/B/BISOPROLOL_SANDOZ-CMI.pdf
[81] 
 Bisoprolol Medication Information Leaflet. National Medication
Information workgroup. The workgroup consists of cluster partners
(National Healthcare Group, National University Health System
and SingHealth), community pharmacies (Guardian, Unity
and Watsons) and Pharmaceutical Society of Singapore 2019.
Available from: https://www.ttsh.com.sg/Patients/and/Visitors/Medical/Services/Pharmacy/Documents/Pharmacy/PIL/PIL%20by%20Drug/Bisoprolol.pdf
[82] 
 MINAX XL (metoprolol succinate) Consumer medicine information
(2020). Alphapharm Pty Ltd, Mylan Inc. Available from: https://media.healthdirect.org.au/medicines/GuildLink_Information/205151/CMI/afcminxl10120.pdf
[83] 
 Metocor (metoprolol tartrate) Package leaflet: Information for the
user (2019). Rowex Ltd. Available from: http://rowex.ie/wp-content/uploads/2019/10/Metocor-50mg-100mg-Tablets-Leaflet.pdf
[84] 
 TOPROL-XL™ (Metoprolol succinate) Consumer Medicine Information.
AstraZeneca 2017. Available from: https://www.news-medical.net/drugs/Toprol-XL.aspx
[85] 
 Metoprolol tartrate. Package leaflet: Information for user (2019).
Accord Healthcare Ltd. Available from: https://www.medicines.org.uk/emc/files/pil.5344.pdf
[86] 
 Metoprolol Sandoz® (Metoprolol tartrate). Consumer Medicine
Information. Published by MIMS 2020. Available from: https://www.nps.org.au/medicine-finder/metoprolol-sandoz-tabletshttps://www.nps.org.au/assets/medicines/9e051f05-976d-4697-a2d9-a53300ff8020-reduced.pdf
[87] 
 Bloxazoc (Metoprolol succinate) Package leaflet: Information
for the user (2015). KRKA, d.d. Available from: https://www.ravimiregister.ee/Data/PIL_ENG/PIL_31809_ENG.pdf
[88] 
 Carvedilol Package leaflet: Information for the user (2019) Milpharm
Limited. Available from: https://www.medicines.org.uk/emc/files/pil.3105.pdf
[89] 
 Carvedilol Package leaflet: Information for the patient (2019)
Mylan. Available from: https://www.medicines.org.uk/emc/files/pil.2547.pdf
[90] 
 Carvedilol Apotex (carvedilol) Package leaflet: Information for the
user (2014) Apotex. Available from: http://mri.ctsmrp.eu/download/NL_H_1633_002_FinalPI_2of4.pdf
[91] 
 AURO-CARVEDILOL (carvedilol) Product monograph; consumer
information (2013). Auro Pharma Inc. Available from: http://www.auropharma.ca/products/monograph/Auro-Carvedilol-PM.pdf
[92] 
 Carvedilol Patient information (2010). Dr. Reddy’s available from: https://www.drreddys.com/media/102860/carvedilol_tablets_usp.pdf
[93] 
 Nebimel (Nebivolol) Package leaflet: Information for the user
(revised in 2020). Clonmel Healthcare Ltd. Available from: https://www.hpra.ie/img/uploaded/swedocuments/7c917f77-c72f-41c1-a67e-b93fcdbb1301.pdf
[94] 
 Nebivolol Package leaflet: Information for the user (2019). Glenmark
Pharmaceuticals Europe Ltd. Available from: https://www.medicines.org.uk/emc/files/pil.9966.pdf
[95] 
 BYSTOLIC® (Nebivolol) Product Monograph. Patient medication information. 2018; 31-5.
[96] 
 Nebivolol (as hydrochloride) Package leaflet: Information for the
user (2018). Glenmark Pharmaceuticals Europe Ltd. Available
from: https://www.medicines.org.uk/emc/files/pil.9967.pdf
[97] 
 Nebivolol Mercury (nebivolol) Package leaflet: Information
for the patient (revised in 2017). Mercury Pharmaceuticals Ltd
available from: https://mri.cts-mrp.eu/human/downloads/DE_H_3840_002_FinalPI_4of4.pdf
[98] 
 Nelet (nebivolol) Package leaflet: Information for the patient (last
revised 2017). McDermott Laboratories Ltd. Available from: https://www.hpra.ie/img/uploaded/swedocuments/PIL-2190766-16062017153500-636332241219218750.pdf
[99] 
 BYSTOLIC® (nebivolol) Highlights of prescribing information
(revised 2011). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021742s013lbl.pdf
[100] 
 Inderal (propranolol hydrochloride) Package leaflet: Information
for the user. AstraZeneca 2018. Available from: https://www.hpra.ie/img/uploaded/swedocuments/92ca6acd-c10b-40f8-b0b9-0f311184dad3.pdf
[101] 
 INDERAL-LA (Propranolol Hydrochloride) Product Monograph. Consumer information. 2016; 28-30.
[102] 
 Propranolol (Propranolol hydrochloride) Consumer Medicine
Information. Apotex Pty Ltd 2018. Available from: https://media.healthdirect.org.au/medicines/GuildLink_Information/222958/CMI/txcpropr10818.pdf
[103] 
 APO-Propranolol Tablets (Propranolol hydrochloride) Consumer
Medicine Information. Published by MIMS 2018. Available from: https://www.nps.org.au/medicinefinder/apopropranololtabletshttps://www.nps.org.au/assets/medicines/1ffdb754-3ac1-4700-ae32-a53300ffb615-reduced.pdf
[104] 
 Hemangiol (Propranolol) Consumer Medicine Information. Published
by MIMS 2018. Available from: https://www.nps.org.au/assets/medicines/264c08ba-eaf5-42fa-a42e-a77000ea8ce8-reduced.pdf
[105] 
 Propranolol (Propranolol hydrochloride) Package leaflet: Information
for the user. Accord Healthcare. 2020. Available from: https://www.medicines.org.uk/emc/files/pil.2903.pdf
[106] 
 Carvedilol phosphate Patient information. Sun Pharmaceutical
Industries, Inc. 2017. Available from: https://www.sunpharma.com/sites/default/files/carvedilol-er-capsules-pil-090132.pdf
[107] 
Bönhof GJ, Herder C, Ziegler D. Diagnostic tools, biomarkers, and treatments in diabetic polyneuropathy and cardiovascular autonomic neuropathy. Curr Diabetes Rev  2022; 18(5): e120421192781.
[http://dx.doi.org/10.2174/1573399817666210412123740] [PMID:  33845748] 
[108] 
Cohen-Hagai K, Fanadka F, Grumberg T, Topaz G, Nacasch N, Greenberg M, et al. Diastolic blood pressure is associated with brain atrophy in hemodialysis patients: A single center case-control study. Ther Apher Dial  2022; 26: 94-102.
[http://dx.doi.org/10.1111/1744-9987.13647] [PMID:  33763913] 
[109] 
Guyenet PG, Stornetta RL. Rostral ventrolateral medulla, retropontine region and autonomic regulations. Auton Neurosci  2022; 237: 102922.
[http://dx.doi.org/10.1016/j.autneu.2021.102922] [PMID:  34814098] 
[110] 
Grotle AK, Macefield VG, Farquhar WB, O’Leary DS, Stone AJ. Recent advances in exercise pressor reflex function in health and dis-ease. Auton Neurosci  2020; 228: 102698.
[http://dx.doi.org/10.1016/j.autneu.2020.102698] [PMID:  32861944] 
[111] 
Min S, Chang RB, Prescott SL, et al. Arterial baroreceptors sense blood pressure through decorated aortic claws. Cell Rep  2019; 29(8): 2192-201.
[http://dx.doi.org/10.1016/j.celrep.2019.10.040] [PMID:  31747594] 
[112] 
Ghitani N, Chesler AT. The anatomy of the baroreceptor reflex. Cell Rep  2019; 29(8): 2121-2.
[http://dx.doi.org/10.1016/j.celrep.2019.11.031] [PMID:  31747586] 
[113] 
Shah-Becker S, Pennock M, Sinoway L, Goldenberg D, Goyal N. Baroreceptor reflex failure: Review of the literature and the potential impact on patients with head and neck cancer. Head Neck  2017; 39(10): 2135-41.
[http://dx.doi.org/10.1002/hed.24857] [PMID:  28675547] 
[114] 
Lauer MS. Heart rate recovery: Coming back full-circle to the baroreceptor reflex. Circ Res  2016; 119(5): 582-3.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309392] [PMID:  27539969] 
[115] 
Silvani A, Calandra-Buonaura G, Benarroch EE, Dampney RA, Cortelli P. Bidirectional interactions between the baroreceptor reflex and arousal: An update. Sleep Med  2015; 16(2): 210-6.
[http://dx.doi.org/10.1016/j.sleep.2014.10.011] [PMID:  25616389] 
[116] 
Reyes del Paso GA, Montoro C, Muñóz Ladrón de Guevara C, Duschek S, Jennings JR. The effect of baroreceptor stimulation on pain perception depends on the elicitation of the reflex cardiovascular response: Evidence of the interplay between the two branches of the baroreceptor system. Biol Psychol  2014; 101: 82-90.
[http://dx.doi.org/10.1016/j.biopsycho.2014.07.004] [PMID:  25038302] 
[117] 
Verberne AJ, Sabetghadam A, Korim WS. Neural pathways that control the glucose counterregulatory response. Front Neurosci  2014; 8: 38.
[http://dx.doi.org/10.3389/fnins.2014.00038] [PMID:  24616659] 
[118] 
Winkler Z, Kuti D, Polyák Á, et al. Hypoglycemia-activated hypothalamic microglia impairs glucose counterregulatory responses. Sci Rep  2019; 9(1): 6224.
[http://dx.doi.org/10.1038/s41598-019-42728-3] [PMID:  30996341] 
[119] 
Nedoboy PE, Cohen M, Farnham MM. Slow but steady-the responsiveness of sympathoadrenal system to a hypoglycemic challenge in ketogenic diet-fed rats. Nutrients  2021; 13(8): 2627.
[http://dx.doi.org/10.3390/nu13082627] [PMID:  34444787] 
[120] 
Mulkey SB, Plessis AD. The critical role of the central autonomic nervous system in fetal-neonatal transition. Semin Pediatr Neurol  2018; 28: 29-37.
[http://dx.doi.org/10.1016/j.spen.2018.05.004] [PMID:  30522725] 
[121] 
Belfort-DeAguiar R, Gallezot JD, Hwang JJ, et al. Noradrenergic activity in the human brain: A mechanism supporting the defense against hypoglycemia. J Clin Endocrinol Metab  2018; 103(6): 2244-52.
[http://dx.doi.org/10.1210/jc.2017-02717] [PMID:  29590401] 
[122] 
Kakall ZM, Kavurma MM, Cohen EM, Howe PR, Nedoboy PE, Pilowsky PM. Repetitive hypoglycemia reduces activation of glucose-responsive neurons in C1 and C3 medullary brain regions to subsequent hypoglycemia. Am J Physiol Endocrinol Metab  2019; 317(2): E388-98.
[http://dx.doi.org/10.1152/ajpendo.00051.2019] [PMID:  31013147] 
[123] 
Güemes A, Georgiou P. Review of the role of the nervous system in glucose homoeostasis and future perspectives towards the manage-ment of diabetes. Bioelectron Med  2018; 4(1): 9.
[http://dx.doi.org/10.1186/s42234-018-0009-4] [PMID:  32232085] 
[124] 
López-Gambero AJ, Martínez F, Salazar K, Cifuentes M, Nualart F. Brain glucose-sensing mechanism and energy homeostasis. Mol Neurobiol  2019; 56(2): 769-96.
[http://dx.doi.org/10.1007/s12035-018-1099-4] [PMID:  29796992] 
[125] 
Raman PG. Central nervous system control of glucose homeostasis. Open J Endocr Metab Dis  2017; 7(12): 227-34.
[http://dx.doi.org/10.4236/ojemd.2017.712020] 
[126] 
Stanley S, Moheet A, Seaquist ER. Central mechanisms of glucose sensing and counterregulation in defense of hypoglycemia. Endocr Rev  2019; 40(3): 768-88.
[http://dx.doi.org/10.1210/er.2018-00226] [PMID:  30689785] 
[127] 
Oshima N, Onimaru H, Matsubara H, et al. Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ven-trolateral medulla in neonatal Wistar rats. Neuroscience  2017; 344: 74-88.
[http://dx.doi.org/10.1016/j.neuroscience.2016.12.039] [PMID:  28062192] 
[128] 
Zhao Z, Wang L, Gao W, et al. A central catecholaminergic circuit controls blood glucose levels during stress. Neuron  2017; 95(1): 138-152.e5.
[http://dx.doi.org/10.1016/j.neuron.2017.05.031] [PMID:  28625488] 
[129] 
Kumagai H, Oshima N, Matsuura T, et al. Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens Res  2012; 35(2): 132-41.
[http://dx.doi.org/10.1038/hr.2011.208] [PMID:  22170390] 
[130] 
Korim WS, Bou Farah L, McMullan S, Verberne AJ. Orexinergic activation of medullary premotor neurons modulates the adrenal sym-pathoexcitation to hypothalamic glucoprivation. Diabetes  2014; 63(6): 1895-906.
[http://dx.doi.org/10.2337/db13-1073] [PMID:  24550189] 
[131] 
Korim WS, Llewellyn-Smith IJ, Verberne AJ. Activation of medulla-projecting perifornical neurons modulates the adrenal sympathetic response to hypoglycemia: Involvement of orexin type 2 (OX2-R) receptors. Endocrinology  2016; 157(2): 810-9.
[http://dx.doi.org/10.1210/en.2015-1712] [PMID:  26653571] 
[132] 
Espinoza L, Fedorchak S, Boychuk CR. Interplay between systemic metabolic cues and autonomic output: Connecting cardiometabolic function and parasympathetic circuits. Front Physiol  2021; 12: 624595.
[http://dx.doi.org/10.3389/fphys.2021.624595] [PMID:  33776789] 
[133] 
Ma Y, Wang Q, Joe D, Wang M, Whim MD. Recurrent hypoglycemia inhibits the counterregulatory response by suppressing adrenal activity. J Clin Invest  2018; 128(9): 3866-71.
[http://dx.doi.org/10.1172/JCI91921] [PMID:  30080182] 
[134] 
Kakall ZM, Nedoboy PE, Farnham MMJ, Pilowsky PM. Activation of µ-opioid receptors in the rostral ventrolateral medulla blocks the sympathetic counterregulatory response to glucoprivation. Am J Physiol Regul Integr Comp Physiol  2018; 315(6): R1115-22.
[http://dx.doi.org/10.1152/ajpregu.00248.2018] 
[135] 
Guyenet PG, Stornetta RL, Holloway BB, Souza GMPR, Abbott SBG. Rostral ventrolateral medulla and hypertension. Hypertension  2018; 72(3): 559-66.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.118.10921] [PMID:  30354763] 
[136] 
Shimazu T, Minokoshi Y. Systemic glucoregulation by glucose-sensing neurons in the Ventromedial Hypothalamic Nucleus (VMH). J Endocr Soc  2017; 1(5): 449-59.
[http://dx.doi.org/10.1210/js.2016-1104] [PMID:  29264500] 
[137] 
Xue B, Zhang Z, Beltz TG, Guo F, Hay M, Johnson AK. Estrogen regulation of the brain renin-angiotensin system in protection against angiotensin II-induced sensitization of hypertension. Am J Physiol Heart Circ Physiol  2014; 307(2): H191-8.
[http://dx.doi.org/10.1152/ajpheart.01012.2013] [PMID:  24858844] 
[138] 
Witt CM, Bolona L, Kinney MO, et al. Denervation of the extrinsic cardiac sympathetic nervous system as a treatment modality for ar-rhythmia. Europace  2017; 19(7): 1075-83.
[http://dx.doi.org/10.1093/europace/eux011] [PMID:  28340164] 
[139] 
Hale GM, Valdes J, Brenner M. The treatment of primary orthostatic hypotension. Ann Pharmacother  2017; 51(5): 417-28.
[http://dx.doi.org/10.1177/1060028016689264] [PMID:  28092986] 
[140] 
Zeng WZ, Marshall KL, Min S, et al. PIEZOs mediate neuronal sensing of blood pressure and the baroreceptor reflex. Science  2018; 362(6413): 464-7.
[http://dx.doi.org/10.1126/science.aau6324] [PMID:  30361375] 
[141] 
La Rovere MT, Pinna GD, Raczak G. Baroreflex sensitivity: Measurement and clinical implications. Ann Noninvasive Electrocardiol  2008; 13(2): 191-207.
[http://dx.doi.org/10.1111/j.1542-474X.2008.00219.x] [PMID:  18426445] 
Rights & Permissions Print Cite
Article Metrics
19
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1381612828666220421135523	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286
Current Pharmaceutical Design

Beta Blockers can Mask not only Hypoglycemia but also Hypotension

Abstract Play Pause

Related Journals

Related Books

Abstract
